| Effect | None |
| Values | Placebo: before 145.77 ± 20.55, after 151.40 ± 20.23. Turmeric: before 136.64 ± 21.57, after 138.95 ± 23.68 |
| Trial Design | Randomized trial |
| Trial Length | 1-6 months |
| Number of Subjects | 80 |
| Sex | Female |
| Age Range | 30-44, 45-64, 65+ |
| Body Types | Obese, Overweight, Average |
In a randomized, double-blind, placebo-controlled trial, 80 hyperlipidemic type 2 diabetes patients were assigned to take 2,100 mg of a powdered rhizome of turmeric or placebo daily for 8 weeks.
The primary outcome was fasting blood glucose and there was no statistically significant difference between groups. There also was no statistically significant difference for HbA1c, insulin, HOMA-IR, or body weight, though there was a significant reduction in body mass index for the turmeric group compared with placebo.
When it came to lipids, the turmeric group saw a large statistically significant reduction in triglycerides compared with placebo, and while there was no change in total cholesterol for turmeric, the placebo group saw an increase, with the difference being statistically significant. There was also a small, statistically significant reduction in LDL-C for turmeric compared with placebo, and there was no difference in Apo-A or B.
There was no statistically significant difference between groups for HS-CRP or total antioxidant capacity.
The primary outcome was fasting blood glucose and there was no statistically significant difference between groups. There also was no statistically significant difference for HbA1c, insulin, HOMA-IR, or body weight, though there was a significant reduction in body mass index for the curcumin group compared with placebo.
When it came to lipids, the curcumin group saw a large statistically significant reduction in triglycerides compared with placebo, and while there was no change in total cholesterol for curcumin, the placebo group saw an increase, with the difference being statistically significant. There was also a small, statistically significant reduction in LDL-C for curcumin compared with placebo, and there was no difference in Apo-A or B.
There was no statistically significant difference between groups for HS-CRP or total antioxidant capacity.
